The Crohn’s disease (CD) therapy market will continue to evolve over the next decade. The well-established tumor necrosis factor-alpha (TNF-α) inhibitors (e.g., Janssen/Merck’s Remicade, AbbVie/Eisai’s Humira) helped transform the treatment landscape, especially for patients with moderate to severe disease, despite their efficacy limitations (e.g., patients lose response over time) and safety risks. Takeda’s Entyvio, a cell adhesion molecule (CAM) inhibitor, which launched in 2014, offered an alternative treatment, especially for patients refractory to TNF-α inhibitors. Most recently, the introduction of the first-in-class interleukin (IL)-12/23 inhibitor, Janssen’s Stelara, has expanded physicians’ treatment armamentarium and will further intensify market competition. Emerging therapies include more-convenient formulations of current agents and drugs with novel mechanisms of action (MOAs) (e.g., Galapagos/Gilead’s filgotinib); these products, together with the increasing availability of biosimilar agents, will further complicate the treatment landscape.
What are key opinion leaders’ (KOLs’) insights on current treatment options for CD (e.g., Remicade, Humira, Inflectra/Remsima)? What factors drive their treatment decisions?
What has been/will be the impact of the newer, non-TNF biologics (e.g., Janssen’s Stelara, Takeda’s Entyvio) on the CD treatment algorithm?
What is KOLs’ opinion of the emerging oral therapies (e.g., Galapagos/Gilead’s filgotinib)? What impact will stem-cell therapies (e.g., TiGenix/Takeda’s Cx-601) have on the CDmarket?
How will the market evolve over the next ten years? What impact will biosimilar agents have on the use of their branded counterparts and on the overall therapy market?
Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.